Bayer Discontinues Hemophilia Study - Analyst Blog
May 06 2013 - 12:40PM
Zacks
Bayer’s (BAYRY)
HealthCare segment recently decided to discontinue the phase II/III
TRUST (TReatment with Unique recombinant rFVIIa STudy) study on BAY
86-6150. The study was evaluating the efficacy and safety of the
candidate in patients suffering from hemophilia A or hemophilia B
with inhibitors.
Bayer stated that a neutralizing
antibody was detected during the course of the study. Since patient
safety was the primary objective of the study, the company
discontinued the BAY 86-6150 trial as a precautionary measure.
Bayer already has Kogenate in its
product portfolio for the treatment of haemophilia. The drug
generated around €1.2 billion in revenues during 2012. Bayer also
has BAY 94-9027 (rFVIII mutein) in its pipeline targeting
hemophilia A. The candidate is currently in phase III
development.
We note that companies like
Biogen Idec Inc. (BIIB) are also developing
therapies targeting the hemophilia market.
Bayer was recently in the news when
it inked a deal to buy Conceptus Inc. (CPTS) for
$31.00 per share or approximately $1.1 billion in cash. Bayer
intends to launch a public tender soon to acquire all shares of
Conceptus. The transaction is expected to close by mid-2013.
Bayer’s impending acquisition of
Conceptus will add the Essure permanent (non-surgical) birth
control system to its product portfolio. We note that Conceptus’
Essure procedure was approved in 2002 in the US and is well
accepted in the market.
Bayer, a large cap pharma company, presently carries a Zacks
Rank #4 (Sell). Other large cap pharma companies such as
Abbvie Inc. (ABBV) currently look more attractive.
Abbvie carries a Zacks Rank #2 (Buy).
ABBVIE INC (ABBV): Free Stock Analysis Report
BAYER A G -ADR (BAYRY): Free Stock Analysis Report
BIOGEN IDEC INC (BIIB): Free Stock Analysis Report
CONCEPTUS INC (CPTS): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
Conceptus, Inc. (MM) (NASDAQ:CPTS)
Historical Stock Chart
From Jun 2024 to Jul 2024
Conceptus, Inc. (MM) (NASDAQ:CPTS)
Historical Stock Chart
From Jul 2023 to Jul 2024